---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-178569"
form_type: "8-K"
ticker: "LITS"
cik: "0001262104"
company_name: "Lite Strategy, Inc."
filed_at: "2023-06-29T23:59:59+00:00"
generated_at: "2026-06-13T14:41:35.864439+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# MEI Pharma urges shareholders to vote FOR Infinity merger ahead of July 14 special meeting

## Summary
- Board reiterates recommendation to approve merger with Infinity Pharmaceuticals (INFI) at July 14 special meeting.
- Combined pipeline includes three clinical-stage programs: eganelisib, voruciclib (with Venclexta), and ME-344 (with Avastin).
- Key data expected from voruciclib and ME-344 by year-end 2023; eganelisib is a Phase 2 first-in-class PI3K-gamma inhibitor.
- Combined company will have experienced drug development team and is positioned to advance diversified oncology pipeline.

## SEC filing metadata
- accession: 0001193125-23-178569
- form_type: 8-K
- ticker: LITS
- cik: 0001262104
- company_name: Lite Strategy, Inc.
- filed_at: 2023-06-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1262104/000119312523178569/0001193125-23-178569-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1262104/000119312523178569/d461231d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-178569
- JSON: https://secwatch.observer/filing/0001193125-23-178569.json
- Plain text: https://secwatch.observer/filing/0001193125-23-178569.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.